Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (211-220 of 386) with videos related to

Pageof 39
Sort By:
Investigational New Drugs|July 7, 2012
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokineticsNwabundo Nwankwo, Zhe Zhang, Ting Wang, et al.
JMIR Research Protocols|October 7, 2024
Correction: Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant CharacteristicsGerald J Jerome, Lawrence J Appel, Linda Bunyard, et al.
Cancer|June 8, 2012
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyEmmanuel S Antonarakis, Daniel Keizman, Zhe Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumorsWells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Investigational New Drugs|April 26, 2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancerMaha Hussain, Michael A Carducci, Susan Slovin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 8, 2022
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testingClaire Snyder, Susan M Hannum, Sharon White, et al.
JMIR Research Protocols|June 12, 2024
Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant CharacteristicsGerald J Jerome, Lawrence J Appel, Linda Bunyard, et al.
JAMA Oncology|July 17, 2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
American Journal of Clinical Oncology|February 22, 2019
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)Mark N Stein, Yu-Hui Chen, Michael A Carducci, et al.
Pageof 39

Showing results (211-220 of 386) with videos related to

Sort By:
Pageof 39
Investigational New Drugs|July 7, 2012
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokineticsNwabundo Nwankwo, Zhe Zhang, Ting Wang, et al.
JMIR Research Protocols|October 7, 2024
Correction: Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant CharacteristicsGerald J Jerome, Lawrence J Appel, Linda Bunyard, et al.
Cancer|June 8, 2012
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyEmmanuel S Antonarakis, Daniel Keizman, Zhe Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumorsWells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Investigational New Drugs|April 26, 2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancerMaha Hussain, Michael A Carducci, Susan Slovin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 8, 2022
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testingClaire Snyder, Susan M Hannum, Sharon White, et al.
JMIR Research Protocols|June 12, 2024
Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant CharacteristicsGerald J Jerome, Lawrence J Appel, Linda Bunyard, et al.
JAMA Oncology|July 17, 2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
American Journal of Clinical Oncology|February 22, 2019
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)Mark N Stein, Yu-Hui Chen, Michael A Carducci, et al.
Pageof 39